《異動股》富智康(02038.HK)曾飆升37%成交創近兩年高 傳富士康擬與吉利組汽車代工合營
富智康(02038.HK)今天價量齊呈異動,股價曾飆升37%至1.39元,創近一年高,現造1.25元,續升21%,成交激增至3.74億股,創21個月高,涉資近4.7億元。此外,鴻騰精密(06088.HK)也扭五連跌,股價重越20天、10天、50天及牛熊線(2.67-2.73元),最高見2.97元,現造2.86元,回升10%,成交急增至6,060萬股,創三個月高,涉資1.71億元。
據《財聯社》報道,吉利控股集團擬與富士康成立一家合營為第三方汽車企業代工,雙方很快將簽署正式協議。另外,據內媒引述知情人士透露,富士康深圳工廠部分車間即將進入iPhone 13打樣第一階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.